Compare · BSX vs DCTH
BSX vs DCTH
Side-by-side comparison of Boston Scientific Corporation (BSX) and Delcath Systems Inc. (DCTH): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BSX and DCTH operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- BSX is the larger of the two at $62.37B, about 92.6x DCTH ($673.8M).
- Over the past year, BSX is down 56.6% and DCTH is up 123.6% - DCTH leads by 180.2 points.
- BSX has been more active in the news (13 items in the past 4 weeks vs 8 for DCTH).
- BSX has more recent analyst coverage (25 ratings vs 4 for DCTH).
- Company
- Boston Scientific Corporation
- Delcath Systems Inc.
- Price
- $43.05-1.50%
- $19.34-2.86%
- Market cap
- $62.37B
- $673.8M
- 1M return
- -4.44%
- +34.59%
- 1Y return
- -56.62%
- +123.58%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 13
- 8
- Recent ratings
- 25
- 4
Boston Scientific Corporation
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, and micro and drainage catheters to treat cancer. The company was founded in 1979 and is headquartered in Marlborough, Massachusetts.
Delcath Systems Inc.
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan hydrochloride for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO includes the FOCUS clinical trial for patients with hepatic dominant ocular melanoma to investigate objective response rate in metastatic ocular melanoma; and the ALIGN trial, a Phase 3 clinical trial for intrahepatic cholangiocarcinoma. The company also provides HEPZATO as a stand-alone medical device for sale under the CHEMOSAT Hepatic Delivery System for Melphalan trade name for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.
Latest BSX
- Boston Scientific Corporation filed SEC Form 8-K: Leadership Update, Other Events, Financial Statements and Exhibits
- Chairman, President & CEO Mahoney Michael F received a gift of 252,241 shares (SEC Form 4)
- SVP, Chief HR Officer O'Sullivan Miriam converted options into 3,871 shares and covered exercise/tax liability with 1,872 shares, increasing direct ownership by 11% to 19,565 units (SEC Form 4)
- Blackstone Life Sciences Announces $455 Million Collaboration to Co-Fund Development of Boston Scientific VITALYST™ Heart Pump for Patients with Cardiogenic Shock
- SEC Form 10-Q filed by Boston Scientific Corporation
- SIMPLAAFY study of the WATCHMAN FLX™ Pro Left Atrial Appendage Closure Device meets primary endpoints
- Boston Scientific downgraded by TD Cowen with a new price target
- Penumbra, Inc. Reports Third Quarter 2026 Financial Results
- Boston Scientific downgraded by Oppenheimer
- Boston Scientific downgraded by Analyst with a new price target
Latest DCTH
- Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Director Martell Bridget A exercised 22,500 shares at a strike of $7.85 and sold $488,508 worth of shares (22,500 units at $21.71) (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13G/A filed by Delcath Systems Inc.
- SEC Form 10-Q filed by Delcath Systems Inc.
- Delcath Systems Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Delcath Systems Reports Third Quarter 2026 Results and Business Highlights
- Delcath Systems to Participate in Upcoming Investor Conferences
- Delcath Systems to Host Third Quarter 2026 Earnings Call
- Delcath Systems Highlights Clinical Program Presentations at ESMO Congress 2026 and Independent Data on Percutaneous Hepatic Perfusion in Liver-Dominant Metastatic Uveal Melanoma
- SEC Form 4 filed by Delcath Systems Inc.